Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
Completed · Phase 4
Conditions studied: Atrial Fibrillation
In brief
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm. HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis) compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion. The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious approach to cardioversion of atrial fibrillation compared to UFH with TEE.
Key facts
- Study ID
- NCT00289042
- Run by
- The Cleveland Clinic
- People needed
- 200
- Starts
- 1999-12-01
- Expected to finish
- 2004-11-01
- Last updated by the study team
- 2007-01-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with chronic or paroxysmal atrial fibrillation of > 2 days duration who are candidates for early chemical or electrical cardioversion
- Patients with atrial flutter with a documented history (electrocardiography) of atrial fibrillation
- Males and females 18 years of age or older
- Patients have available results of routine clinical labs for standard clinical chemistry and complete blood count within the previous 14 days
You may not qualify if…
- An INR > 1.4 in patients who have received warfarin prior to enrollment.
- Use of IV heparin for more than 72 hours immediately prior to randomization.
- Patients with contraindications to TEE, such as dysphagia, or esophageal strictures.
- Patients who will need anticoagulation discontinued because of elective intervening procedure, such as cardiac catheterization or surgery.
- Patients with contraindications to warfarin or heparin
- Patients who require concomitant therapy during the study period with any drug known to affect coagulation or platelet function (i.e. ASA, NSAID, antiplatelet drugs)
- Women of childbearing potential, unless pregnancy can be excluded by medical history incompatible with pregnancy or by serum or urine beta HCG levels.
- Patients who are hemodynamically unstable and thus may require immediate cardioversion.
- Weight less than 40 kg (88 pounds) or more than 125 kg (275 pounds)
- History of gastrointestinal bleeding disorder and/or endoscopically verified ulcer disease within the last year
- History of intracranial or retinal bleeding, or other known disorders with an increased risk of bleeding
- Ischemic stroke in the previous three months
- Uncontrolled hypertension (systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 100 mm Hg)
- Malignancy currently under active treatment, including melanoma
- Patients with renal insufficiency (creatinine > 2.0 mg/dL) or are renal transplant subjects
- Patients with anemia (Hgb less than 10 gm/dL)
- Patients with thrombocytopenia (platelet count less than 100 x 10\^9/L)
- Positive fecal hemoglobin test
- Life expectancy of less than 6 months
- History of drug and/or alcohol abuse within the last two years
- Patients unable or unwilling to give informed consent
- Patients unable or unwilling to return for follow-up
- Prisoners or wards of the state
- Patients with psychological problems that may decrease compliance with the protocol
- Not willing to complete the Quality of Life Questionnaires x 3
Where it is running
- Cleveland Clinic — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.